Madrigal Pharma (MDGL) option IV into FDA approves Madrigal Pharmaceuticals' Rezdiffra
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
Madrigal Pharma (NASDAQ: MDGL) 30-day option implied volatility is at 151; compared to its 52-week range of 49 to 176 into FDA approves Madrigal Pharmaceuticals' Rezdiffra.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vail Resorts (MTN) call put ratio 1 call to 1 put amid price movement
- Qualcomm (QCOM) call put ratio 3.6 calls to 1 put with a focus on 2K contracts of July 2 weekly 270 calls as share price up 4.6%
- FedEx (FDX) call put ratio 1 call to 1.5 puts into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
